Stuertz K, Merx I, Eiffert H, Schmutzhard E, Mäder M, Nau R
Department of Neurology, University of Göttingen, Germany.
J Clin Microbiol. 1998 Aug;36(8):2346-8. doi: 10.1128/JCM.36.8.2346-2348.1998.
A newly developed enzyme immunoassay (EIA) was used to detect the presence of pneumococcal teichoic and lipoteichoic acids in cerebrospinal fluid (CSF) from patients with Streptococcus pneumoniae meningitis who were being treated with antibiotics. All initial CSF samples, which on culture grew S. pneumoniae, were positive in the EIA. A total of 14 subsequent culture-negative samples gave clear signals in the EIA up to day 15 after the onset of antibiotic treatment. For 11 CSF specimens, culture, microscopy, and latex agglutination were negative while the EIA detected pneumococcal antigens. The EIA did not react either with CSF of patients with meningitis caused by bacteria other than S. pneumoniae or by viral pathogens. In conclusion, this EIA can be a valuable tool for the diagnosis of S. pneumoniae meningitis from CSF samples in cases in which prior antimicrobial therapy minimizes the usefulness of culture or other antigen detection tests.
一种新开发的酶免疫测定法(EIA)被用于检测正在接受抗生素治疗的肺炎链球菌脑膜炎患者脑脊液(CSF)中肺炎球菌磷壁酸和脂磷壁酸的存在。所有最初培养出肺炎链球菌的脑脊液样本,在EIA检测中均呈阳性。在抗生素治疗开始后的第15天,总共14份随后培养结果为阴性的样本在EIA检测中给出了清晰的信号。对于11份脑脊液标本,培养、显微镜检查和乳胶凝集试验均为阴性,但EIA检测到了肺炎球菌抗原。EIA对由非肺炎链球菌的细菌或病毒病原体引起的脑膜炎患者的脑脊液均无反应。总之,在先前的抗菌治疗使培养或其他抗原检测试验的效用降低的情况下,这种EIA可成为从脑脊液样本诊断肺炎链球菌脑膜炎的有价值工具。